Argenta Limited

argentaglobal.com

Argenta: A Pharmaceutical CRO and CMO Dedicated to Animal Health. Argenta offers a full range of contract services - from pre-clinical development through to commercial product manufacture and more. Our products and services are exported to more than 40 countries, including the United States, Canada, Europe and Japan.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

AMYLYX PHARMACEUTICALS ANNOUNCES ALBRIOZA™ IS NOW AVAILABLE IN CANADA FOR THE TREATMENT OF ALS

Amylyx Pharmaceuticals, Inc | August 01, 2022

news image

Amylyx Pharmaceuticals, Inc. announced that ALBRIOZA™ is now commercially available in Canada for people living with amyotrophic lateral sclerosis. ALBRIOZA is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments. In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS. “We have remained steadfast in our commitment ...

Read More

Business Insights

IKTOS ANNOUNCES COLLABORATION WITH GALAPAGOS IN AI FOR DRUG DESIGN

Iktos, | June 29, 2022

news image

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies and software ...

Read More

ORION BIOTECHNOLOGY SUCCESSFULLY ACCOMPLISHES PHASE 1 CLINICAL TRIAL OF A FIRST-IN-CLASS PRECISION ENGINEERED LIGAND ANALOG FOR HIV PREVENTION

Orion Biotechnology Canada Ltd | October 16, 2020

news image

Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H gel. OB-002, a highly potent chemokine analog of CCL5 (a ligand for the CCR5 HIV co-receptor), has previ...

Read More

Pharma Tech

WCG ANNOUNCES PARTNERSHIP WITH MINT MEDICAL TO SUPPORT IMAGING IN ONCOLOGY CLINICAL TRIALS

PRNewswire | June 29, 2023

news image

WCG, one of the world's leading providers of solutions that measurably improve the quality, efficiency, and safety of clinical research, recently announced a partnership with Mint Medical to leverage its mint Lesion™ radiology platform for oncology trials. The mint Lesion™ software is used for standardized and computer-assisted review of medical imaging according to defined protocols, guidelines, and workflows. Compliant and highly configurable, mint Lesion&trade...

Read More
news image

Business Insights

AMYLYX PHARMACEUTICALS ANNOUNCES ALBRIOZA™ IS NOW AVAILABLE IN CANADA FOR THE TREATMENT OF ALS

Amylyx Pharmaceuticals, Inc | August 01, 2022

Amylyx Pharmaceuticals, Inc. announced that ALBRIOZA™ is now commercially available in Canada for people living with amyotrophic lateral sclerosis. ALBRIOZA is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments. In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS. “We have remained steadfast in our commitment ...

Read More
news image

Business Insights

IKTOS ANNOUNCES COLLABORATION WITH GALAPAGOS IN AI FOR DRUG DESIGN

Iktos, | June 29, 2022

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies and software ...

Read More
news image

ORION BIOTECHNOLOGY SUCCESSFULLY ACCOMPLISHES PHASE 1 CLINICAL TRIAL OF A FIRST-IN-CLASS PRECISION ENGINEERED LIGAND ANALOG FOR HIV PREVENTION

Orion Biotechnology Canada Ltd | October 16, 2020

Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H gel. OB-002, a highly potent chemokine analog of CCL5 (a ligand for the CCR5 HIV co-receptor), has previ...

Read More
news image

Pharma Tech

WCG ANNOUNCES PARTNERSHIP WITH MINT MEDICAL TO SUPPORT IMAGING IN ONCOLOGY CLINICAL TRIALS

PRNewswire | June 29, 2023

WCG, one of the world's leading providers of solutions that measurably improve the quality, efficiency, and safety of clinical research, recently announced a partnership with Mint Medical to leverage its mint Lesion™ radiology platform for oncology trials. The mint Lesion™ software is used for standardized and computer-assisted review of medical imaging according to defined protocols, guidelines, and workflows. Compliant and highly configurable, mint Lesion&trade...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us